Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lowered its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 249,622 shares of the company’s stock after selling 3,153 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Johnson & Johnson were worth $66,085,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in the stock. Outlook Capital Management LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $28,000. Matrix Trust Co raised its holdings in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares during the period. Montgomery Financial Services LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $43,000. Polaris Financial Partners acquired a new stake in Johnson & Johnson in the 3rd quarter valued at about $56,000. Finally, Bullseye Investment Management LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at about $63,000. Institutional investors and hedge funds own 69.55% of the company’s stock.
Johnson & Johnson Trading Up 0.9%
Shares of JNJ stock opened at $271.17 on Thursday. Johnson & Johnson has a fifty-two week low of $184.66 and a fifty-two week high of $281.07. The stock’s fifty day moving average price is $265.60 and its two-hundred day moving average price is $246.26. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The company has a market cap of $652.78 billion, a PE ratio of 41.09, a P/E/G ratio of 2.61 and a beta of 0.21.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s payout ratio is presently 81.21%.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. The trade was a 48.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 64,515 shares of company stock worth $17,271,766. Insiders own 0.16% of the company’s stock.
Trending Headlines about Johnson & Johnson
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: JNJ is included among pharmaceutical companies with potential arthritis-treatment growth, supported by drug sales, clinical progress and regulatory expansion. This reinforces the outlook for its Innovative Medicine business and future cash generation. The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
- Positive Sentiment: The company will hold an Enterprise Business Review on December 8, when management is expected to provide additional detail on its Innovative Medicine and MedTech pipelines, long-term strategy and growth opportunities. The event could offer catalysts if the company raises confidence in future earnings. Johnson & Johnson to Host Enterprise Business Review
- Neutral Sentiment: JNJ has gained roughly 97% over three years, prompting investors to assess whether its valuation is supported by expected cash flow. Oncology trial developments and MedTech performance could materially influence that assessment. Johnson & Johnson Stock Trades At A Discount Following Its 97% Run
- Negative Sentiment: Ongoing attention to a talc-related charge adds legal and cash-flow uncertainty, while investors continue to monitor the broader talc litigation overhang. What Does the Talc Charge Mean for Johnson & Johnson Going Forward?
- Negative Sentiment: Reports of approximately $34.7 million in net ETF selling represent a modest technical headwind, although such flows do not necessarily reflect a change in JNJ’s fundamentals. Johnson & Johnson Sees $34.7 Million in Net ETF Selling
- Negative Sentiment: Pomerantz LLP is investigating potential claims on behalf of JNJ investors. The announcement does not establish wrongdoing, but it adds to headline and litigation risk. Investor Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Johnson & Johnson
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on JNJ shares. Scotiabank reissued an “outperform” rating and set a $305.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. Wells Fargo & Company raised their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research report on Friday, October 16th. Argus set a $300.00 target price on Johnson & Johnson in a research note on Wednesday, July 29th. UBS Group set a $270.00 target price on Johnson & Johnson in a research note on Wednesday, October 14th. Finally, Erste Group Bank lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $275.92.
View Our Latest Analysis on JNJ
About Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.
Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.
Read More
- Five stocks we like better than Johnson & Johnson
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
